Entreprise · 14/09/20101 min de lecture
Prospective Grant of Exclusive License: Development of AAV5 Based Therapeutics To Treat Human Diseases
Traduction automatique locale · Langue originale de la source
Résumé
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the invention embodied in U.S. Patent 6, 984, 517, entitled "AAV5 and Uses Thereof," U.S. Patent 7, 479, 554, entitled "AAV5 Nucleic Acids" and PCT Application Serial No. PCT/US99/11958 and foreign equivalents thereof, entitled "AAV5 and Uses Thereof" [HHS Ref. No. E-127-1998/0]; and U.S. Patent 6, 855, 314 entitled "AAV5 Vector for Transducing Brain Cells and Lung Cells" [HHS Ref. No. E-072-2000/0] to Amsterdam Molecular Therapeutics, which is located in Amsterdam, The Netherlands. The Government of the United States of America has the right to license these patent rights. The prospective exclusive license territory may be worldwide, and the field of use may be limited to the development and sale of AAV5 based therapeutic products to be delivered to the brain, eyes and liver for treatment of diseases originated from these organs, as claimed in the Licensed Patent Rights.